Panacea Pharmaceuticals, Inc. Presents Data That Its Cancer Biomarker HAAH is Readily Detectable in Serum Exosomes

Thursday, March 30, 2017 Drug News
Email Print This Page Comment
Font : A-A+

Improved Detection of Exosomal HAAH is Presented at the American Association for Cancer Research (AACR) Meeting in Washington, DC, April 2, 2017

GAITHERSBURG, Md., March 30, 2017 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. presents a paper regarding detection

of the cancer biomarker HAAH at the annual American Association for Cancer Research (AACR) meeting in Washington DC held April 1-5, 2017. The paper is titled:

"Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase (HAAH)"

The paper demonstrates major refinements to Panacea's multi-cancer HAAH-exosome detection assay that targets the cancer-specific blood serum biomarker HAAH. The cancer field is intensely focused upon exosomes, which are small cell-like nanoparticles derived from the cancer cells that are proving to be important biomarkers and mediators of cancer cell metastasis and progression.

The association of Panacea's target molecule HAAH with exosomes has led to a better individual understanding of these biomarkers as well as further development of a markedly improved diagnostic test with higher sensitivity and specificity than previous versions of the assay.

"We are excited to report our continued advances in the understanding of the role of serum exosomes in the detection and monitoring of cancer," said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel biologically targeted cancer therapies and diagnostics for unmet medical needs and is headquartered in Gaithersburg, Md. The company has recently initiated a Phase 1 trial of its PAN-301-1 therapeutic cancer vaccine in prostate cancer patients and has late-nonclinical stage projects in serodiagnosis of cancer, immuno-imaging of cancer, monoclonal antibody-based immunotherapy of cancer and neuroprotection, specifically in prevention of chemotherapy-induced cognitive impairment and peripheral neuropathy.

Contact:  Steven Fuller, Panacea Pharmaeceuticals, Inc., 240-454-8010, sfuller@panaceapharma.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/panacea-pharmaceuticals-inc-presents-data-that-its-cancer-biomarker-haah-is-readily-detectable-in-serum-exosomes-300431997.html

SOURCE Panacea Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook